Therapy News and Research

RSS

Health Canada approves Afinitor for treatment of brain tumours caused by TSC in children

Families with children suffering from brain tumours caused by an uncommon genetic disorder known as Tuberous Sclerosis Complex (TSC) have new hope with Health Canada's recent conditional approval of a new therapeutic use for the drug Afinitor (everolimus). Afinitor is the first drug therapy approved in Canada for the treatment of brain tumours caused by TSC in patients three years of age and older.

14 Sep 2011

Mary Ann Liebert launches 'Human Gene Therapy Methods' journal

Mary Ann Liebert, Inc. announces the launch of a journal expansion, Human Gene Therapy Methods, to complement the flagship publication Human Gene Therapy.

14 Sep 2011

VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting

VIVUS, Inc. today presented positive results from the avanafil phase 3 study in diabetics. In the REVIVE-Diabetes study (TA-302), male diabetics receiving avanafil had significant improvement in erectile function.

14 Sep 2011

ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE

ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.

14 Sep 2011

Rehabilitation the ‘great missing link’ in the healthcare system Leading physicians convene in Brisbane today

The lack of publically funded community-based rehabilitation and restorative programs is one of the great missing links in the Australian health care system, according to leading Australian physicians.

13 Sep 2011

New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress

Bayer HealthCare announced today that the company will present data on several of its investigational compounds at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.

13 Sep 2011

Researchers use MRI and PET/CT to assess safety, efficacy of heart drug dalcetrapib

Researchers from Mount Sinai School of Medicine have for the first time used several imaging techniques to prove the efficacy of a promising new treatment for atherosclerosis—the build-up of plaque in artery walls that can lead to a heart attack.

13 Sep 2011

Majority of cryoballoon ablation patients show no signs of A-Fib year after procedure

Many patients are responding to a new, minimally invasive way of treating irregular heartbeats by freezing out the bad cells. Atrial fibrillation (A-Fib) is one such heart rhythm disorder, and it's the most common arrhythmia affecting Americans.

13 Sep 2011

Roundup: Ga. rejects rule to curb dental hygienists' work; Ohio high-risk pool faces higher than expected costs

The Georgia Board of Dentistry on Friday rejected a proposed rule that public health officials feared would have restricted dental hygienists' work with low-income patients. Several health groups had said the provision, if approved, would require a dentist to examine a patient before a hygienist can apply sealants, clean teeth and perform other preventive dental services in a public health setting.

13 Sep 2011

Government funding crisis in Swaziland disrupts supply of HIV/AIDS supplies

"An acute government funding crisis in Swaziland, Africa's last absolute monarchy, is disrupting supplies of HIV/AIDS drugs and hampering the fight against the virus in the country with the world's highest infection rate, Medecins Sans Frontieres (MSF) said Friday," Reuters reports.

12 Sep 2011

Low-dose aspirin increases risk for GI bleeding

The risk of gastrointestinal (GI) bleeding needs to be considered when determining the potential preventive benefits associated with low-dose aspirin for cardiovascular disease and cancer.

12 Sep 2011

Publix to offer Bioject ZetaJet for flu immunizations

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, announced today that beginning in September 2011, select Publix Super Markets (Publix) in the Southeast region will be offering flu season immunizations utilizing the Bioject ZetaJet™. Publix will be conducting evaluations in 52 stores in Florida, Georgia, Alabama and South Carolina.

12 Sep 2011

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

Oncothyreon Inc. today announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.

12 Sep 2011

BioSante reports top-line results from LibiGel PK study for HSDD in postmenopausal women

BioSante Pharmaceuticals, Inc., today announced successful completion of its principal LibiGel (testosterone gel) pharmacokinetic (PK) study.

12 Sep 2011

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.

12 Sep 2011

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Alchemia Limited, today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug HA-Irinotecan in Small Cell Lung Cancer (SCLC). Two patients have received their first doses of therapy. This investigator sponsored trial is being conducted at Monash Cancer Centre, Southern Health and Peninsula Oncology Centre in Melbourne, Victoria.

12 Sep 2011

Valeritas completes Series C round of financing

Valeritas, Inc., a medical technology company focused on the development and commercialization of innovative drug delivery solutions, announced today it has completed a significant Series C round of financing of $150 million.

12 Sep 2011

IsoRay receives FDA clearance for GliaSite radiation therapy system to treat brain cancer

IsoRay, Inc. announced today that the FDA has cleared its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer.

12 Sep 2011

Spinifex announces new data from EMA401 pre-clinical study on diabetic neuropathy

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces the presentation of new data from a study of EMA401 in a model of diabetic neuropathy.

12 Sep 2011

Heart attack patients with psoriasis more likely to die from cardiovascular disease

Heart attack patients with psoriasis are 26 per cent more likely to die from cardiovascular disease, or suffer from recurrent heart attacks or strokes, and are 18 per cent more likely to die from all causes than those without the inflammatory skin disease.

12 Sep 2011

Therapy News and Research

Health Canada approves Afinitor for treatment of brain tumours caused by TSC in children

Mary Ann Liebert launches 'Human Gene Therapy Methods' journal

VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting

ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE

Rehabilitation the ‘great missing link’ in the healthcare system Leading physicians convene in Brisbane today

New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress

Researchers use MRI and PET/CT to assess safety, efficacy of heart drug dalcetrapib

Majority of cryoballoon ablation patients show no signs of A-Fib year after procedure

Roundup: Ga. rejects rule to curb dental hygienists' work; Ohio high-risk pool faces higher than expected costs

Government funding crisis in Swaziland disrupts supply of HIV/AIDS supplies

Low-dose aspirin increases risk for GI bleeding

Publix to offer Bioject ZetaJet for flu immunizations

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

BioSante reports top-line results from LibiGel PK study for HSDD in postmenopausal women

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Valeritas completes Series C round of financing

IsoRay receives FDA clearance for GliaSite radiation therapy system to treat brain cancer

Spinifex announces new data from EMA401 pre-clinical study on diabetic neuropathy

Heart attack patients with psoriasis more likely to die from cardiovascular disease

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News